GlassScriptPhysician profile
Michelle Adams
NPI 1790957165
$5,372.79
in general payments reported to CMS, 2019-2025
22 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $601 · 2022: $1,082 · 2023: $1,289 · 2024: $957 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,689.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,717.84 | 2021-2025 | Lumigan, Alphagan P, Durysta |
| Oyster Point Pharma, INC. | $842.12 | 2022-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $758.30 | 2021-2023 | |
| Allergan, INC. | $401.20 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $342.25 | 2022-2025 | Envista Aspire Iol, Stellaris, Miebo |
| Alcon Vision LLC | $313.25 | 2023-2025 | Eysuvis, Simbrinza, Rocklatan |
| Sun Pharmaceutical Industries INC. | $286.19 | 2023-2025 | Cequa |
| Rxsight INC | $130.96 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Light Adjustable Lens (Rxlal) |
| Mallinckrodt Hospital Products INC. | $112.25 | 2023-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $61.61 | 2025 | Iluvien |
| Eyevance Pharmaceuticals LLC | $50.87 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $50.46 | 2025 | Xdemvy |
| Genentech USA, INC. | $48.59 | 2024 | Vabysmo |
| Harrow Eye, LLC | $42.96 | 2024-2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $37.14 | 2024-2025 | Syfovre |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.20 | 2025 | Izervay |
| Dompe US, INC. | $30.55 | 2025 | Oxervate |
| Boston Scientific Corporation | $29.21 | 2025 | Watchman Flx |
| Kala Pharmaceuticals, INC. | $23.15 | 2021 | |
| Amgen INC. | $22.38 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.89 | 2021 | |
| Sight Sciences, INC. | $17.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.